Fibrocell Science Inc (FCSC)

[THREE-DAY-TRADER]

That was a relatively very positive earnings report this morning with multiple good updates in it, regardless of how the market may react yet going forward.
It decreased costs substantially & guided with plenty of cash thru 4th Qtr 2019 (after many recent share offerings).
$FCSC also updated well on clinical developments including an enrollment initiated just recently in August.


Fibrocell Science 2nd Qtr - 2018 Financial Results (8/09/18)

“Our FCX-013 gene therapy program for the treatment of moderate to severe localized scleroderma also made notable progress this quarter. The U.S. Food and Drug Administration (FDA) allowed our Investigational New Drug application earlier this year, and in August, we initiated the first investigator site for clinical enrollment for our open label, single arm Phase 1/2 clinical trial,”